MONT-SAINT-HILAIRE, QUEBEC--(MARKET WIRE)--Jun 21, 2007 -- Axcan Pharma Inc. (“Axcan” or the “Company”) (Toronto:AXP.TO - News)(NasdaqGS:AXCA - News) today announced that it has filed the Chemistry, Manufacturing and Control data (“CMC”) portion of its New Drug Application (“NDA”) for ULTRASE in the treatment of Exocrine Pancreatic Insufficiency (“EPI”), with the U.S. Food and Drug Administration (“FDA”). The Company plans to submit the complete and final NDA dossier to the FDA in the weeks to come. Axcan also announced that the FDA has granted the product a Fast Track designation. Fast Track designations allow promising new drugs and biological products that treat serious, life-threatening or severely debilitating diseases to proceed more rapidly through the regulatory process.
